tetano
Editor, Senior Moderator
J Med Virol
. 2020 Aug 10.
doi: 10.1002/jmv.26408. Online ahead of print.
Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis
Soumya Sarkar[SUP] 1 [/SUP], Kapil Dev Soni[SUP] 2 [/SUP], Puneet Khanna[SUP] 1 [/SUP]
Affiliations
Abstract
Background: In absence of definitive therapy for coronavirus disease (COVID-19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID-19 patients based on the publications reported to date.
Methods: A robust screening of electronic databases was conducted up to 10[SUP]th[/SUP] July 2020. The randomized controlled trials (RCTs), cohort studies, and case series with control group evaluating the effectiveness and safety of CPT in patients with COVID-19 are included for the meta-analyses.
Results: Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5,444 patients. In patients with COVID-19, the use of CPT reduces mortality [Odd's ratio (OR) 0.44, 95% CI 0.25 to 0.77], increases viral clearance [OR 11.29, 95% CI 4.9 to 25.9] and improves clinically [OR 2.06, 95% CI 0.8 to 4.9].However, the evidences are of low quality (mortality reduction, and viral clearance),and very low quality (clinical improvement).
Conclusions: CPT may be beneficial for reducing mortality, viral shedding. and improving clinical conditions in COVID-19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT. This article is protected by copyright. All rights reserved.
Keywords: (COVID-19): coronavirus disease; (CPT): convalescent plasma therapy; (SARS-CoV-2): severe acute respiratory syndrome coronavirus-2.
. 2020 Aug 10.
doi: 10.1002/jmv.26408. Online ahead of print.
Convalescent plasma a clutch at straws in COVID-19 management! A systematic review and meta-analysis
Soumya Sarkar[SUP] 1 [/SUP], Kapil Dev Soni[SUP] 2 [/SUP], Puneet Khanna[SUP] 1 [/SUP]
Affiliations
- PMID: 32776573
- DOI: 10.1002/jmv.26408
Abstract
Background: In absence of definitive therapy for coronavirus disease (COVID-19), convalescent plasma therapy (CPT) may be a critical therapeutic option. This review was conducted to evaluate the impact of CPT in COVID-19 patients based on the publications reported to date.
Methods: A robust screening of electronic databases was conducted up to 10[SUP]th[/SUP] July 2020. The randomized controlled trials (RCTs), cohort studies, and case series with control group evaluating the effectiveness and safety of CPT in patients with COVID-19 are included for the meta-analyses.
Results: Our search retrieved seven studies, including two RCTs and five cohort studies, with a total of 5,444 patients. In patients with COVID-19, the use of CPT reduces mortality [Odd's ratio (OR) 0.44, 95% CI 0.25 to 0.77], increases viral clearance [OR 11.29, 95% CI 4.9 to 25.9] and improves clinically [OR 2.06, 95% CI 0.8 to 4.9].However, the evidences are of low quality (mortality reduction, and viral clearance),and very low quality (clinical improvement).
Conclusions: CPT may be beneficial for reducing mortality, viral shedding. and improving clinical conditions in COVID-19 patients. However, further randomized control trials (RCT) are required to substantiate the safety margin, initiation, optimal dosage, titre and duration of CPT. This article is protected by copyright. All rights reserved.
Keywords: (COVID-19): coronavirus disease; (CPT): convalescent plasma therapy; (SARS-CoV-2): severe acute respiratory syndrome coronavirus-2.